Skip to Content

Briviact Approval History

FDA Approved: Yes (First approved February 19, 2016)
Brand name: Briviact
Generic name: brivaracetam
Company: UCB, Inc.
Treatment for: Epilepsy

Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.

Development History and FDA Approval Process for Briviact

DateArticle
May 14, 2018Approval UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients
Sep 15, 2017Approval FDA Approves New indication for Briviact (brivaracetam) as Monotherapy Treatment of Partial-Onset Seizures in Adults
Feb 19, 2016Approval FDA Approves Briviact (brivaracetam) to Treat Partial Onset Seizures
Jan 21, 2015UCB Announces US and EU Regulatory Filings for the Investigational Antiepileptic Drug Brivaracetam
Dec  8, 2014Data from Phase 3 Study Evaluating Brivaracetam as Adjunctive Treatment of Partial-Onset Seizures

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide